Orthopediatrics (KIDS) Issues Quarterly Earnings Results, Meets Expectations

Orthopediatrics (NASDAQ:KIDS) issued its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.19), Briefing.com reports. The company had revenue of $14.60 million for the quarter, compared to analysts’ expectations of $14.50 million. Orthopediatrics had a negative return on equity of 65.26% and a negative net margin of 55.97%. The firm’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.41) earnings per share. Orthopediatrics updated its FY 2019 guidance to EPS.

Shares of KIDS stock opened at $40.43 on Thursday. The firm has a market capitalization of $536.23 million, a P/E ratio of -7.09 and a beta of 0.11. Orthopediatrics has a twelve month low of $14.00 and a twelve month high of $43.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.23 and a current ratio of 5.67.

A hedge fund recently raised its stake in Orthopediatrics stock. Geode Capital Management LLC grew its stake in Orthopediatrics Corp (NASDAQ:KIDS) by 51.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 80,310 shares of the company’s stock after acquiring an additional 27,429 shares during the quarter. Geode Capital Management LLC owned 0.63% of Orthopediatrics worth $2,801,000 at the end of the most recent quarter. 44.00% of the stock is owned by institutional investors.

KIDS has been the topic of several recent research reports. BidaskClub raised Orthopediatrics from a “hold” rating to a “buy” rating in a research note on Thursday, December 20th. BTIG Research upped their price target on Orthopediatrics to $37.00 and gave the stock a “buy” rating in a research note on Wednesday, January 2nd. Zacks Investment Research raised Orthopediatrics from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a research note on Wednesday, January 2nd. Finally, JMP Securities initiated coverage on Orthopediatrics in a research note on Wednesday, February 20th. They issued an “outperform” rating and a $44.00 price target on the stock. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Orthopediatrics currently has a consensus rating of “Buy” and an average target price of $37.25.

WARNING: This story was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.chaffeybreeze.com/2019/03/07/orthopediatrics-kids-issues-quarterly-earnings-results-meets-expectations.html.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

See Also: Why do companies issue convertible shares?

Earnings History for Orthopediatrics (NASDAQ:KIDS)

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.